Dermatology and Venereology Insights: Melanoma Treatment Breakthroughs

1. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Authors: Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al.
Journal: The New England journal of medicine
PMID: 39282897
DOI: 10.1056/NEJMoa2407417


2. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Authors: Tawbi HA, Schadendorf D, Lipson EJ, et al.
Journal: The New England journal of medicine
PMID: 34986285
DOI: 10.1056/NEJMoa2109970


3. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
Authors: Larkin J, Chiarion-Sileni V, Gonzalez R, et al.
Journal: The New England journal of medicine
PMID: 26027431
DOI: 10.1056/NEJMoa1504030


4. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Authors: Patel SP, Othus M, Chen Y, et al.
Journal: The New England journal of medicine
PMID: 36856617
DOI: 10.1056/NEJMoa2211437


5. Systemic Photoprotection in Melanoma and Non-Melanoma Skin Cancer.
Authors: Hyeraci M, Papanikolau ES, Grimaldi M, et al.
Journal: Biomolecules
PMID: 37509103
DOI: 10.3390/biom13071067